Mortality from COVID-19 in patients with lung cancer

Amit A. Kulkarni1, Grace Wilson2, Naomi Fujioka1, Manish R. Patel1

1Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
2University of Minnesota Medical School, Minneapolis, MN 55455, USA.

Correspondence to: Assist. Prof. Amit A. Kulkarni M.D., Division of Hematology, Oncology, Transplant, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA. E-mail: kulkarni@umn.edu


Received: 5 Feb 2021 First Decision: 13 Apr 2021 Revised: 6 May 2021 Accepted: 19 May 2021 Published: 11 Jun 2021

Abstract
The World Health Organization declared coronavirus infectious disease-2019 (COVID-19) linked to the severe acute respiratory syndrome (SARS-CoV-2), a global pandemic in March 2020. The pandemic outbreak has led to the most unprecedented and catastrophic loss of human life in the recent history. As of January 2021, there were more than 100 million cases of COVID-19 and more than two million deaths worldwide. Compared to the general population, patients with cancer are at a higher risk of poor outcomes from COVID-19. In large cohort studies, mortality from COVID-19 in patients with cancer can be as high as 40%. In addition to clinical variables (older age, male sex, and co-morbidities) that are associated with mortality in general population, cancer patients are uniquely vulnerable to severe COVID-19 due to immunosuppression from cancer and its therapy, and disruption of routine clinical care. Among patients with cancer, the lung cancer population is at a higher risk of poor outcomes and mortality from COVID-19 for several reasons. For instance, lung is the main target organ in COVID-19 that can lead to respiratory failure, patients with lung cancer have baseline poor lung function from chronic obstructive pulmonary disorder and smoking. In addition, some of the lung cancer treatment side-effects like pneumonitis, may obscure the diagnosis of COVID-19. In this article, we systematically review the most impactful cohort studies published to date in patients with cancer and COVID-19. We describe the rates of mortality in patients with cancer and COVID-19 with a special focus on the lung cancer population. We also summarize the factors associated with poor outcomes and mortality in patients with lung cancer and COVID-19.

Keywords: Coronavirus, COVID-19, lung cancer, mortality
INTRODUCTION

Lung cancer is the leading cause of cancer-related death worldwide with approximately 136,000 deaths estimated in 2020 in the United States alone\(^1\). Coronavirus disease-2019 (COVID-19) is a respiratory tract infection caused by the novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) that has quickly escalated into a global pandemic after initial outbreak in Wuhan province, China in December 2019. The United States was the epicenter of the outbreak, with more than 25 million people testing positive for COVID-19 and more than 400,000 deaths attributed to COVID-19 as of January 2021\(^2\). COVID-19 severity can range widely from an asymptomatic or mild flu-like illness to respiratory failure and severe acute respiratory distress syndrome. Large cohort studies have shown that clinical factors consistently associated with increased risk of death from COVID-19 include older age, male sex, and comorbidities such as hypertension, diabetes, obesity, and cancer\(^3,4\). Biomarkers associated with poor outcomes include lymphocytopenia, elevated D-Dimer, elevated C-reactive protein, elevated cardiac troponin and elevated interleukin-6\(^5,6\). Patients with cancer are highly vulnerable to COVID-19 due to their immunocompromised state, frequent contact with the health care system, advanced age and comorbidities, putting them in the highest-risk category for COVID-19-related morbidity and mortality. During the early phase of the pandemic, there were limited data on the impact of COVID-19 in patients with cancer. Recent studies have consistently shown increased rates of hospitalization, higher COVID-19-related mortality and higher all-cause mortality in patients with cancer\(^7-15\). In published studies, the mortality of cancer patients with COVID-19 can range from 16% to as high as 40%\(^7-15\). While patients with cancer clearly have worse outcomes from COVID-19, data on patients with lung cancer and COVID-19 are limited. Available data suggest that patients with lung cancer may be at a higher risk of severe COVID-19 infection due to compromised lung function from smoking and chronic obstructive pulmonary disorder (COPD)\(^11,16\). In addition, patients with lung cancer often have symptoms that overlap with COVID-19, potentially causing a delay in diagnosis. Furthermore, radiographic findings of COVID-19 may be difficult to distinguish from pneumonitis caused by immunotherapy, radiation, or targeted therapies for lung cancer. In this article, we provide a comprehensive review of the literature related to COVID-19 and cancer and report data specific for COVID-19 mortality in patients with lung cancer.

EVIDENCE FROM LARGE COVID-19 AND CANCER COHORT STUDIES - FOCUSING ON LUNG CANCER

Early reports from China showed a higher burden of COVID-19 in patients with cancer\(^17\) but were limited by sample size, short follow-up time and lack of information on cancer status and cancer-specific treatment. Recently, several large, multi-institutional cohort studies dedicated to cancer patients with COVID-19 have provided more insights on the risk factors associated with a worse outcome [Table 1]. One of the first large cohort studies reported was from Wuhan, China which compared 105 patients with COVID-19 and cancer to 536 age-matched controls without any cancer\(^9\). In the study, patients with cancer had higher death rates [Odds ratio (OR) = 2.34, 95% confidence interval (CI): 1.15-4.77, \(P = 0.03\)], higher rates of intensive care unit (ICU) admission (OR = 2.84, 95%CI: 1.59-5.08, \(P < 0.01\)), and higher chances of requiring invasive mechanical ventilation. The mortality was 11.4% in patients with cancer compared to 4.9% in those without cancer. In this study, lung cancer was the most prevalent cancer type (20.95%), followed by gastrointestinal cancer (12.38%) and breast cancer (10.48%). Patients with lung cancer had the second-highest risk for adverse outcomes; the mortality was 18.1%, the ICU admission rate was 27.2%, and 18.1% required mechanical ventilation. In another study across 9 hospitals in Hubei province, China, clinical outcomes of 205 patients with cancer and COVID-19 were reported\(^13\). The majority of patients had solid tumor malignancies (89%); breast cancer (20%), colorectal (14%) and lung cancer (12%) were the most common malignancies. The overall mortality rate was 20% across all cancer types. However, those with lung cancer had the highest mortality of 25%. Multivariable regression analysis showed that receiving cytotoxic
chemotherapy (but not targeted therapy) within 4 weeks before symptom onset (OR = 3.51, 95%CI: 1.16-10.59, \( P = 0.026 \)) and male sex (OR = 3.86, 95%CI: 1.57-9.50, \( P = 0.0033 \)) were associated with increased mortality.

In the United States, one of the first studies to report experience with cancer and COVID-19 was the single-institution study from the Montefiore Health system in New York, NY, the epicenter of infection in the early stages of the pandemic. In this study, 218 patients with cancer and COVID-19 were included\(^\text{[10]}\). The mortality was 28\% across all cancers. Amongst patients with solid tumor malignancies, the eleven patients with lung cancer had the highest mortality (55\%). In the multivariate model, older age (age < 65, OR = 0.23, 95%CI: 0.07-0.6), higher composite comorbidity score (composite score defined as the sum of indicators for diabetes mellitus, hypertension, chronic lung disease, chronic kidney disease, coronary artery disease, and congestive heart failure capped at a maximum of 3) (OR = 1.52, 95%CI: 1.02-2.33), ICU admission (OR = 4.83, 95%CI: 1.46-17.15), and elevated inflammatory markers (D-dimer, lactate, and lactate dehydrogenase) were significantly associated with mortality. Advanced metastatic disease and active disease showed a trend for increased mortality but did not meet statistical significance. Similarly, active chemotherapy or radiation treatment was not associated with increased fatality. The number of patients on immunotherapy was negligible.

Another single-institution study from New York showed that patients with lung cancer (\( N = 102 \)) and COVID-19 had high rates of hospitalization (65\%) and death (25\%)\(^\text{[16]}\). Similar to other studies, advancing age (OR = 2.01, 95%CI: 1.34-3.19), smoking history [OR = 2.9, 95%CI: 1.07-9.44, comparing the median (23.5 pack-years) to never-smoker], COPD (OR = 3.87, 95%CI: 1.35-9.68), and hypertension (OR = 2.68, 95%CI: 1.14-6.14) were associated with increased risk of severe COVID-19. Active/metastatic lung cancer, history of prior thoracic radiation or thoracic surgery did not appear to impact the severity of COVID-19 infection. Another smaller study in patients with lung cancer (\( N = 41 \)) who received immunotherapy showed numerical increase in COVID-19 severity (univariate OR, 1.18-1.81 for severity outcomes); however, when adjusted for smoking history, immunotherapy exposure did not significantly impact risk of hospitalization, ICU admission, or death\(^\text{[18]}\).

COVID-19 and Cancer Consortium (CCC-19) from the US, and the United Kingdom Coronavirus Cancer Monitoring Project (UKCCMP) are the two largest pan-cancer cohorts to study the impact of cancer on COVID-19 infection. The UKCCMP study analyzed 800 patients with a diagnosis of cancer and
symptomatic COVID-19\cite{8}. The mortality was 28% amongst these patients. Patients with lung cancer had mortality of 14%, whereas mortality of patients with gastrointestinal cancers was 19%. Mortality was significantly associated with advanced age (OR = 9.42, 95%CI: 6.56-10.02, \(P < 0.0001\)), male sex (OR = 1.67, 95%CI: 1.19-2.34, \(P = 0.003\)), and comorbidities such as hypertension (OR = 1.95, 95%CI: 1.36-2.80, \(P < 0.001\)) and cardiovascular disease (OR = 2.32, 95%CI: 1.47-3.64). When compared to patients who did not receive recent chemotherapy, patients who received cytotoxic chemotherapy within 4 weeks of a diagnosis of COVID-19 (\(N = 281\), 35%) did not appear to have a greater COVID-19 related mortality (OR = 1.18, 95%CI: 0.81-1.72, \(P = 0.380\)). Similarly, there was no significant effect on mortality associated with other classes of cancer therapy such as immunotherapy, hormonal therapy, targeted therapy, or radiotherapy use within 4 weeks of COVID-19 diagnosis. However, the number of patients on these therapies was low (< 10% for each therapy). Further details specifically on patients with lung cancer were not published.

Initial results from CCC-19 included 928 patients with cancer and lab-confirmed COVID-19 accrued through April 2020. Breast (20%) and prostate (16%) cancers were most prevalent, and thoracic malignancies comprised 10% of the cohort\cite{7}. By the time of data analysis, 242 patients (26%) had met the composite outcome of death, severe illness requiring hospitalization, and/or mechanical ventilation. Thirty-day mortality rate was 13% (\(N = 121\)). Multivariable analysis demonstrated that independent factors associated with increased 30-day mortality were increased age (per 10 years, OR = 1.84, 95%CI: 1.53-2.21), male sex (OR = 1.63, 95%CI: 1.07-2.48), smoking status (former smoker vs. never smoked: OR = 1.60, 95%CI: 1.03-2.47), the number of comorbidities (two vs. none: OR = 4.50, 95%CI: 1.33-15.28), Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher (status of 2 vs. 0 or 1: OR = 3.89, 95%CI: 2.11-7.18), active cancer (progressing vs. remission: OR = 5.20, 95%CI: 2.77-9.77), and receipt of azithromycin plus hydroxychloroquine (vs. treatment with neither: OR = 2.93, 95%CI: 1.79-4.79). Subgroup analysis showed that neither cancer type nor its treatment was associated with 30-day all-cause mortality; however, due to limited statistical power, extensive analysis (e.g., comparing patients with thoracic malignancies to others) was not feasible. The most updated analysis included 2749 patients with cancer and COVID-19\cite{19}. Twenty-nine percent (\(N = 810\)) of the patients had met the composite outcome of death, severe illness requiring hospitalization, and/or mechanical ventilation. Overall, 30-day all-cause mortality for the CCC-19 cohort increased to 16% (\(N = 433\)) and about 60% (\(N = 1637\)) of the patients required hospitalization. These increases are presumably due to longer median follow-up, as opposed to a general worsening of COVID-19. Factors associated with an increased 30-day mortality were similar. However, none of the cancer therapies (cytotoxic chemotherapy, immunotherapy, targeted therapy, endocrine therapies, and radiation) were independently associated with an increased risk of 30-day all-cause mortality. In this cohort, patients with lung cancer had one of the highest mortality rates of 26% (\(N = 61\) of 237), while thyroid and breast cancer had the lowest mortality rate among all malignancies (3% and 8%, respectively).

Thus far, the largest dataset dedicated to lung cancer and COVID-19 is the TERAVOLT (Thoracic Cancers International COVID-19 collaboration) global registry, which has provided a greater understanding of the patient- and cancer-specific risk factors in patients with lung cancer suffering from COVID-19 infection\cite{11}. The TERAVOLT study initially reported 200 patients with thoracic cancers and COVID-19 across 8 countries, the vast majority had non-small cell lung cancer (\(N = 151\) (76%), 147 (74%)) had stage 4 disease and 147 (74%) were on active systemic cancer treatment. Similar to CCC-19, the hospitalization rates were striking (76%), and overall mortality was as high as 33%. On multivariable analysis, only smoking was associated with increased risk of mortality (OR = 3.18, 95%CI: 1.11-9.06). More importantly, any systemic therapy, including targeted therapies (28/147, 19%), chemotherapy (48/147, 33%), and immunotherapy (23%) or combination chemo-immunotherapy (14%), did not affect survival in patients with COVID-19. An updated analysis of 400 patients in TERAVOLT was presented at the American society of clinical oncology
Hospitalization rates (78%) and overall mortality were similar (35%) to the previously published data. However, in the updated analysis, patients with age > 65 (OR = 1.70, 95%CI: 1.09-2.63, \( P = 0.018 \)), presence of comorbidities, ECOG PS ≥ 1 (OR = 2.14, 95%CI: 1.11-4.11, \( P < 0.001 \)), use of steroids (equivalent of prednisone > 10 mg/day) (OR = 1.49, 95%CI: 1.00-2.23, \( P = 0.052 \)) and anticoagulation prior to COVID-19 diagnosis were associated with increased risk of death. As opposed to earlier analysis, prior administration of chemotherapy (alone or with immunotherapy) within 3 months of COVID-19 diagnosis (OR = 1.71, 95%CI: 1.12-2.63, \( P = 0.025 \)) was associated with increased risk of death. Whereas receipt of immunotherapy or targeted therapy did not increase risk for mortality. In a sub-group analysis, patients with rare thoracic malignancies (small cell lung cancer, mesothelioma) appeared to have mortality of 40%\(^[21]\). Furthermore, TERAVOLT recently presented updated analysis from 1053 patients at the 2020 World Conference on Lung Cancer meeting\(^[22]\). The overall mortality was similar to that in the previous studies (33%). On multivariate analysis, male sex, older age, worse performance status, and four or more metastatic sites were associated with increased risk of death. Race and ethnicity did not seem to affect the risk of death. Full results of this data are awaiting publication. Table 2 summarizes the factors associated with severe COVID-19 and or mortality across all the studies.

CONCLUSIONS

Metanalyses of independent studies have consistently shown high mortality in patients with cancer and COVID-19. For instance, in a metanlyses study of 2922 patients across 18 studies, the pooled 30-day mortality rate was 30% in hospitalized patients where as it was about 15% among patients who were treated either in hospital or outpatient setting\(^[23]\). In another metanalysis of 15 studies among 3019 patients, the mortality rate was 22.4%\(^[24]\). In both studies a higher mortality was associated with older age and male gender. In comparison to other cancers, patients with lung cancer and COVID-19 particularly have a disproportionately higher mortality ranging from 11% to 40%. Amongst all studies, clinical factors consistently associated with increased risk of severe COVID-19 or death in lung cancer patients include advancing age, and comorbidities such as hypertension or smoking history. In the largest studies to date in lung cancer population, use of cytotoxic chemotherapy (alone or in combination with immunotherapy) has shown increased risk for mortality\(^[25]\). In contrast, none of the other studies or metanlyses\(^[25]\) reported this association with the caveat that most of these studies were across all cancers. Reassuringly, use of immunotherapy or targeted therapy was not convincingly associated with increased mortality in any studies. While these data may be limited by short follow-up time, it suggests that providers should not withhold or delaying lung cancer treatment significantly due to the risk of COVID-19. The pandemic has resulted in substantial challenges to cancer care delivery leading to significant delays in screening and diagnosis, systemic therapy, and curative intent surgery. The long-term impact of this delay has yet to be determined. National and international societies like ASCO, National comprehensive cancer network and European society of medical oncology have issued guidelines for lung cancer care during the COVID-19 pandemic based on risk stratification, comorbidities, and stage of cancer\(^[26-28]\). While COVID-19 infection is potentially disproportionately life-threatening for patients with lung cancer, the risks in delaying cancer care can likewise result in devastating outcomes. As we evolve and adapt to emerging data, we encourage institutions to continue to approach the treatment of patients with lung cancer in an individualized, multidisciplinary approach. While highly effective vaccines are currently being rolled out, and bring hope to patients and providers alike, it is projected that several more months will pass before high-risk patients such as those with lung cancer will have access to the vaccine. Therefore, ongoing mitigation efforts like mask or face covering, physical distancing, and optimizing virtual care will continue to be fundamental in the fight against the COVID-19 pandemic and its devastating impact on patients with cancer.
Table 2. Factors associated with severe COVID-19 and or mortality on multivariable regression analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Cancer type</th>
<th>Factors associated with severe COVID-19 and or mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yang et al.</td>
<td>All cancers (N = 105)</td>
<td>Age Male gender Smoking Others ECOG status Cancer status Laboratory variables For COVID For cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA OR = 3.86 (1.57-9.50, P = 0.0033) NA NA NA NA NA NA Cytotoxic chemotherapy* (OR = 3.51, 95%CI: 1.16-10.59, P = 0.026)</td>
</tr>
<tr>
<td>Mehta et al.</td>
<td>All cancers (N = 105)</td>
<td>Age &lt; 65 (OR = 0.23, 95%CI: 0.07-0.6) NA NA NA - Higher composite comorbidity score** (OR = 1.52, 95%CI: 1.02-2.33) NA NA Elevated D-dimer, lactate, and LDH NA</td>
</tr>
<tr>
<td>Luo et al.</td>
<td>Lung cancer (N = 101)</td>
<td>Advancing age (OR = 2.01, 95%CI: 1.34-3.19) OR 2.9, 95%CI: 1.07-9.44) - COPD (OR = 3.87, 95%CI: 1.35-9.68) - HTN (OR = 2.68, 95%CI: 1.14-6.14) NA NA NA NA NA</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>All cancers (N = 800)</td>
<td>OR = 9.42, 95%CI: 6.56-10.02, P &lt; 0.0001 OR = 1.67 (1.19-2.34), P = 0.003) - HTN (OR = 1.95, 1.36-2.80, P &lt; 0.001) - CVD (OR = 2.32, 1.47-3.64) NA NA NA NA NA</td>
</tr>
<tr>
<td>Kuderer et al.</td>
<td>All cancers (N = 928)</td>
<td>Increased age (OR = 1.84, 95%CI: 1.53-2.21) OR = 1.63, 95%CI: 1.07-2.48 OR = 1.60, 95%CI: 1.03-2.47 Number of comorbidities (two vs. none: OR = 4.50, 95%CI: 1.33-15.28) Number of comorbidities (two vs. none: OR = 4.50, 95%CI: 1.33-15.28) ECOG 2 or more (OR = 3.89, 95%CI: 2.11-7.18) - Active cancer (progressing vs. remission: OR = 5.20, 95%CI: 2.77-9.77) Azithromycin + hydroxychloroquine (vs. treatment with neither: OR = 2.93, 95%CI: 1.79-4.79) Use of steroids (equivalent of prednisone &gt; 10 mg/day) (OR = 1.49, 95%CI: 1.00-2.23, P = 0.052) Chemo-therapy (+ or - immunotherapy) (OR = 1.71, 95%CI: 1.12-2.63, P = 0.025)</td>
</tr>
<tr>
<td>Garassino et al.</td>
<td>Lung cancer (N = 400)</td>
<td>Age &gt; 65 (OR = 1.70, 95%CI: 1.09-2.63, P = 0.018) NA NA NA ECOG ≥ 1 (OR = 2.14, 95%CI: 1.11-4.11, P &lt; 0.001) NA NA NA</td>
</tr>
</tbody>
</table>

* Only positive associations reported. **Within 4 weeks before symptom onset; **Composite score defined as the sum of indicators for diabetes mellitus (DM), hypertension, chronic lung disease, chronic kidney disease, coronary artery disease, and congestive heart failure capped at a maximum of 3. NA: Not applicable; OR: odds ratio; CI: confidence interval; ICU: intensive care unit; LDH: lactate dehydrogenase; COPD: chronic obstructive pulmonary disease; HTN: hypertension; ECOG: Eastern Cooperative Oncology Group.
DECLARATIONS

Authors’ contributions
Extracting data and literature review: Kulkarni AA, Wilson G, Fujioka N, Patel MR
Manuscript writing and editing: Kulkarni AA, Wilson G, Fujioka N, Patel MR

Availability of data and materials
Not applicable.

Financial support and sponsorship
Kulkarni AA - University of Minnesota COVID-19 Rapid Response grant.

Conflicts of interest
The authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES